ESC 365 - Predictors of warfarin discontinuation or switching among non-valvular atrial fibrillation patients

ESC Premium Access

Predictors of warfarin discontinuation or switching among non-valvular atrial fibrillation patients

Session: Poster session 4 - Stroke prevention

Topic: Atrial fibrillation (AF)

Speaker: Doctor X. Luo (Groton, US)

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Doctor Xuemei Luo

Groton (United States of America)

0 follower

53 more presentations in this session

Differences between randomized controlled clinical trials and real-world atrial fibrillation patients treated with oral anticoagulants - do we treat the same patients? Results from the CRAFT study

Speaker: Doctor A. Tyminska (Warsaw, PL)

Which factors influence the choice of a non-vitamin K oral anticoagulant over warfarin for stroke prevention among atrial fibrillation patients? Insights from the prospective SPRINT-AF registry.

Speaker: Doctor M. Gupta (Toronto, CA)

Real-world effectiveness of stroke prevention in patients with non-valvular atrial fibrillation treated with rivaroxaban vs. phenprocoumon in germany - insights from the reload study

Speaker: Professor H. Bonnemeier (Luebeck, DE)

Increased thromboprophylactic treatment of patients with atrial fibrillation after the introduction of NOACs - an analysis of sex and gender differences

Speaker: Ms D. Loikas (Stockholm, SE)

Comparison of stroke- and bleed-related healthcare resource utilization (HCRU) among patients with non-valvular atrial fibrillation (NVAF), newly treated with oral anti-coagulants (OACs)

Speaker: Doctor J. Franchino-Elder (Ridgefield, US)

Access the full session

Poster session 4 - Stroke prevention

Speakers: Doctor X. Luo, Doctor A. Tyminska, Doctor M. Gupta, Professor H. Bonnemeier, Ms D. Loikas...

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources